Henry Schein Inc. (HSIC) faced a 3.9% drop following their last earnings report and their Q4 sales reported slightly lower than analyst estimates. However, they recently announced a significant collaboration with investment firm KKR, affirming KKR's strategic investment valued at $250M and the company's representation in HSIC's board seats. Henry Schein reported strong global sales growth in Q4 2024 and released Q4 outlook, including Wall Street's estimates for key metrics. HSIC's acquisition of Acentus is now complete, expanding their portfolio of homecare medical products. Their innovative '3-Click Dentistry' solution is transforming oral health practice, and the firm also received validation for their Net-Zero Science-based targets. The healthcare solutions leader received recognition from FORTUNE for their 14-year ethical leadership streak and $22.6M social impact, emphasizing their commitment to corporate citizenship. The company also strengthened their emergency response efforts with their 'Prepare to Care' program. Looking ahead, the company's earnings quality is providing comfort for investors alongside robust 2025 financial guidance. Despite mixed financials and confrontation from activist investor Ananym, HSIC remains a top value stock for long-term investors.
Henry Schein HSIC News Analytics from Wed, 10 Jul 2024 07:00:00 GMT to Tue, 15 Apr 2025 12:31:56 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor 2
